Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

Background: Rituximab (Mabthera™) have been in use in India since 2000. A biosimilar molecule of rituximab (Reditux™) was approved in India in 2007. This retrospective audit was done to compare the efficacy and safety of Mabthera™ with Reditux™. Materials and Methods: We reviewed the charts of 223 a...

Full description

Saved in:
Bibliographic Details
Main Authors: Partha Sarathi Roy, Shiji John, Sadashiv Karankal, Sadhana Kannan, Preeti Pawaskar, Jayanta Gawande, Bhausaheb Bagal, Navin Khattry, Manju Sengar, Hari Menon, Sumeet Gujral, Reena Nair
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2013-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Anti-CD20
biosimilar
lymphoid neoplasms
monoclonal antibody
observational study
survival outcomes
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=4;spage=292;epage=298;aulast=Roy
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=4;spage=292;epage=298;aulast=Roy

Similar Items